AR127861A2 - Composición farmacéutica que comprende inhibidores del proteasoma peptídico y ciclodextrina - Google Patents
Composición farmacéutica que comprende inhibidores del proteasoma peptídico y ciclodextrinaInfo
- Publication number
- AR127861A2 AR127861A2 ARP220103323A ARP220103323A AR127861A2 AR 127861 A2 AR127861 A2 AR 127861A2 AR P220103323 A ARP220103323 A AR P220103323A AR P220103323 A ARP220103323 A AR P220103323A AR 127861 A2 AR127861 A2 AR 127861A2
- Authority
- AR
- Argentina
- Prior art keywords
- cyclodextrin
- proteasome inhibitors
- pharmaceutical composition
- composition including
- including peptide
- Prior art date
Links
- 229920000858 Cyclodextrin Polymers 0.000 title abstract 3
- 229940079156 Proteasome inhibitor Drugs 0.000 title abstract 3
- 239000003207 proteasome inhibitor Substances 0.000 title abstract 3
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 title abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 1
- VNDHXHMRJVTMTK-WZVRVNPQSA-H hexasodium 4-[[(1S,3R,5R,6S,8R,10R,11S,13R,15R,16S,18R,20R,21S,23R,25R,26S,28R,30R,31S,33R,35R,36R,37R,38R,39R,40R,41R,42R,43R,44R,45R,46R,47R,48R,49R)-36,37,38,39,40,41,42,43,44,45,46,47,48,49-tetradecahydroxy-10-(hydroxymethyl)-15,20,25,30,35-pentakis(4-sulfonatobutoxymethyl)-2,4,7,9,12,14,17,19,22,24,27,29,32,34-tetradecaoxaoctacyclo[31.2.2.23,6.28,11.213,16.218,21.223,26.228,31]nonatetracontan-5-yl]methoxy]butane-1-sulfonate Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].OC[C@H]1O[C@@H]2O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCCCCS([O-])(=O)=O)O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCCCCS([O-])(=O)=O)O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCCCCS([O-])(=O)=O)O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCCCCS([O-])(=O)=O)O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCCCCS([O-])(=O)=O)O[C@H]3[C@H](O)[C@@H](O)[C@H](O[C@@H]3COCCCCS([O-])(=O)=O)O[C@H]1[C@H](O)[C@H]2O VNDHXHMRJVTMTK-WZVRVNPQSA-H 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- -1 sulfobutyl b-cyclodextrin Chemical compound 0.000 abstract 1
Classifications
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
- A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nanotechnology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medical Informatics (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
Abstract
La presente divulgación proporciona procedimientos para formular composiciones que comprenden uno o más inhibidores del proteasoma peptídico y una ciclodextrina, en particular una ciclodextrina sustituida. Dichos procedimientos incrementan considerablemente la solubilidad y la estabilidad de estos inhibidores del proteasoma y facilitan tanto su fabricación como su administración. Reivindicación 1: Una composición farmacéutica, caracterizada porque comprende: (a) un compuesto: de fórmula (1); y (b) sulfobutil b-ciclodextrina que tiene un contenido de iones cloruro de 0,05 p/p o menos (SBECD con bajos niveles de cloruro); en la forma de un liofilizado.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261644122P | 2012-05-08 | 2012-05-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR127861A2 true AR127861A2 (es) | 2024-03-06 |
Family
ID=49549072
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120103377A AR087863A1 (es) | 2012-05-08 | 2012-09-13 | Procedimientos para la formacion de complejos de ciclodextrina para formular inhibidores del proteasoma peptidico |
| ARP220103323A AR127861A2 (es) | 2012-05-08 | 2022-12-02 | Composición farmacéutica que comprende inhibidores del proteasoma peptídico y ciclodextrina |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP120103377A AR087863A1 (es) | 2012-05-08 | 2012-09-13 | Procedimientos para la formacion de complejos de ciclodextrina para formular inhibidores del proteasoma peptidico |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US20130303465A1 (es) |
| JP (1) | JP2015516416A (es) |
| KR (1) | KR20150007361A (es) |
| CN (1) | CN103781490A (es) |
| AR (2) | AR087863A1 (es) |
| AU (1) | AU2012238318B2 (es) |
| BR (1) | BR112012028726B1 (es) |
| CA (1) | CA2793894A1 (es) |
| CO (1) | CO6571868A2 (es) |
| CR (1) | CR20120485A (es) |
| CU (1) | CU20120159A7 (es) |
| DO (1) | DOP2012000252A (es) |
| EA (1) | EA201201519A1 (es) |
| EC (1) | ECSP12012167A (es) |
| MA (1) | MA35238B1 (es) |
| MX (1) | MX2012010891A (es) |
| MY (2) | MY196510A (es) |
| SG (1) | SG194417A1 (es) |
| TW (1) | TWI603737B (es) |
| WO (1) | WO2013169282A1 (es) |
| ZA (1) | ZA201207384B (es) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7635773B2 (en) | 2008-04-28 | 2009-12-22 | Cydex Pharmaceuticals, Inc. | Sulfoalkyl ether cyclodextrin compositions |
| DK2814849T3 (da) | 2012-02-15 | 2020-03-09 | Cydex Pharmaceuticals Inc | Fremgangsmåde til fremstilling af cyclodextrin-derivater |
| AR095426A1 (es) | 2013-03-14 | 2015-10-14 | Onyx Therapeutics Inc | Inhibidores tripeptídicos de la epoxicetona proteasa |
| WO2014152127A1 (en) | 2013-03-14 | 2014-09-25 | Onyx Therapeutics, Inc. | Dipeptide and tripeptide epoxy ketone protease inhibitors |
| GB201312737D0 (en) | 2013-07-17 | 2013-08-28 | Univ Greenwich | Cyclodextrin |
| WO2015009888A2 (en) | 2013-07-19 | 2015-01-22 | Onyx Therapeutics, Inc. | Peptide epoxyketone proteasome inhibitors in combination with pim kinase inhibitors for treatment of cancers |
| CN104945470B (zh) * | 2014-03-30 | 2020-08-11 | 浙江大学 | 杂环构建的三肽环氧酮类化合物及制备和应用 |
| CN103936828A (zh) * | 2014-05-12 | 2014-07-23 | 苏州科耐尔医药科技有限公司 | 卡非佐米中间体及卡非佐米的制备方法 |
| CN105919972A (zh) * | 2015-12-18 | 2016-09-07 | 重庆两江药物研发中心有限公司 | 一种包载卡非佐米的纳米粒制剂及其制备方法 |
| TWI759301B (zh) | 2016-05-24 | 2022-04-01 | 美商安美基公司 | 聚乙二醇化卡非佐米化合物 |
| US11708341B2 (en) | 2016-08-05 | 2023-07-25 | Amgen Inc. | Synthesis of (S)-2-amino-4-methyl-((R)-2-methyloxirane-2-yl)-pentan-1-one and pharmaceutically acceptable salts thereof |
| WO2018038687A1 (en) | 2016-08-22 | 2018-03-01 | Mustafa Nevzat Ilaç Sanayii A.Ş. | Pharmaceutical formulations comprising a bortezomib-cyclodextrin complex |
| WO2018183686A1 (en) * | 2017-03-31 | 2018-10-04 | Valent Biosciences Llc | 1-aminocyclopropane-1-carboxylic acid polymorphs |
| US10975121B2 (en) | 2017-06-24 | 2021-04-13 | Cytogel Pharma, Llc | Analgesic mu-opioid receptor binding peptide pharmaceutical formulations and uses thereof |
| CN111344018A (zh) | 2017-11-16 | 2020-06-26 | 美国安进公司 | 聚乙二醇化卡非佐米化合物的稳定的组合物 |
| EP3716948B1 (en) * | 2017-11-30 | 2023-11-22 | Cytogel Pharma, LLC | Novel analgesic pharmaceutical formulations and uses thereof |
| KR20230029789A (ko) * | 2020-06-19 | 2023-03-03 | 암젠 인크 | 카르필조밉의 측정 방법 |
| US11246874B1 (en) | 2021-04-20 | 2022-02-15 | Oxygen Biotech LLC | Treatment of COVID-19 |
| CN113406183B (zh) * | 2021-06-29 | 2024-04-23 | 常州磐诺仪器有限公司 | 基于离子淌度质谱仪高效识别青霉胺手性对映体的方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE499109T1 (de) * | 2004-12-07 | 2011-03-15 | Proteolix Inc | Zusammensetzung zur proteasomhemmung |
| PL2623113T3 (pl) * | 2005-11-09 | 2018-05-30 | Onyx Therapeutics, Inc. | Związek do hamowania enzymu |
| KR20170125413A (ko) * | 2007-10-04 | 2017-11-14 | 오닉스 세라퓨틱스, 인크. | 결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성 |
-
2012
- 2012-09-13 KR KR1020127028681A patent/KR20150007361A/ko not_active Application Discontinuation
- 2012-09-13 SG SG2012084075A patent/SG194417A1/en unknown
- 2012-09-13 MY MYPI2017001061A patent/MY196510A/en unknown
- 2012-09-13 CN CN201280001354.7A patent/CN103781490A/zh active Pending
- 2012-09-13 US US13/614,599 patent/US20130303465A1/en not_active Abandoned
- 2012-09-13 WO PCT/US2012/055127 patent/WO2013169282A1/en active Application Filing
- 2012-09-13 MY MYPI2012005407A patent/MY165002A/en unknown
- 2012-09-13 EA EA201201519A patent/EA201201519A1/ru unknown
- 2012-09-13 TW TW101133449A patent/TWI603737B/zh active
- 2012-09-13 AR ARP120103377A patent/AR087863A1/es not_active Application Discontinuation
- 2012-09-13 MX MX2012010891A patent/MX2012010891A/es not_active Application Discontinuation
- 2012-09-13 CA CA2793894A patent/CA2793894A1/en not_active Abandoned
- 2012-09-13 US US13/614,829 patent/US20130303482A1/en not_active Abandoned
- 2012-09-13 JP JP2015511431A patent/JP2015516416A/ja active Pending
- 2012-09-13 AU AU2012238318A patent/AU2012238318B2/en active Active
- 2012-09-13 BR BR112012028726-5A patent/BR112012028726B1/pt active IP Right Grant
- 2012-09-26 CR CR20120485A patent/CR20120485A/es unknown
- 2012-09-26 EC ECSP12012167 patent/ECSP12012167A/es unknown
- 2012-09-27 DO DO2012000252A patent/DOP2012000252A/es unknown
- 2012-09-28 CO CO12170407A patent/CO6571868A2/es not_active Application Discontinuation
- 2012-10-02 ZA ZA2012/07384A patent/ZA201207384B/en unknown
- 2012-11-12 CU CU2012000159A patent/CU20120159A7/es unknown
-
2013
- 2013-12-04 MA MA36520A patent/MA35238B1/fr unknown
-
2022
- 2022-12-02 AR ARP220103323A patent/AR127861A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2012238318A1 (en) | 2013-11-28 |
| MX2012010891A (es) | 2014-03-05 |
| SG194417A1 (en) | 2013-12-30 |
| MA35238B1 (fr) | 2014-07-03 |
| AR087863A1 (es) | 2014-04-23 |
| US20130303482A1 (en) | 2013-11-14 |
| NZ602490A (en) | 2016-03-31 |
| KR20150007361A (ko) | 2015-01-21 |
| AU2012238318B2 (en) | 2014-02-13 |
| TW201345543A (zh) | 2013-11-16 |
| CA2793894A1 (en) | 2013-11-08 |
| CU20120159A7 (es) | 2014-03-26 |
| BR112012028726A2 (pt) | 2016-07-19 |
| CN103781490A (zh) | 2014-05-07 |
| CR20120485A (es) | 2013-12-18 |
| US20130303465A1 (en) | 2013-11-14 |
| CO6571868A2 (es) | 2012-11-30 |
| ECSP12012167A (es) | 2013-02-28 |
| TWI603737B (zh) | 2017-11-01 |
| MY165002A (en) | 2018-02-28 |
| EA201201519A1 (ru) | 2013-11-29 |
| ZA201207384B (en) | 2018-12-19 |
| WO2013169282A1 (en) | 2013-11-14 |
| JP2015516416A (ja) | 2015-06-11 |
| MY196510A (en) | 2023-04-18 |
| DOP2012000252A (es) | 2013-12-31 |
| BR112012028726B1 (pt) | 2021-07-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR127861A2 (es) | Composición farmacéutica que comprende inhibidores del proteasoma peptídico y ciclodextrina | |
| AR122746A2 (es) | Una formulación farmacéutica líquida estable de anticuerpo | |
| CY1122786T1 (el) | Δοσολογικα σχηματα για ενωσεις κατηγοριας εχινοκανδινης | |
| CY1121882T1 (el) | Αναστολεις πυραζολυλο κινοξαλινο κινασης | |
| CY1119435T1 (el) | Σκευασμα για αντισωμα εναντι- αλφα4βητα7 | |
| DOP2016000071A (es) | Inhibidores de tirosina cinasa de bruton | |
| CY1122483T1 (el) | Λυοφιλοποιημενες παρασκευες μελφαλανης φλουφεναμιδης | |
| PE20160605A1 (es) | Formulaciones de inhibidores de la syk | |
| UY35353A (es) | Un inhibidor de mdm2 derivado de ácido benzoico para el tratamiento del cáncer | |
| CL2017003456A1 (es) | Metodos para tratar tumores de celulas epitelioides | |
| EA202092456A3 (ru) | Комбинированная терапия, включающая ингибитор mdm2 и один или более дополнительных фармацевтически активных агентов, для лечения различных видов рака | |
| ECSP15004752A (es) | Formulaciones de etanercept que muestran una marcada reducción de la cantidad de partículas subvisibles | |
| CU24350B1 (es) | DERIVADOS DE 5-HETEROARIL-4-FENIL-4,5-DIHIDROPIRROLO(3,4-c)PIRAZOL-6-ONA ACTIVOS COMO INHIBIDORES DE BET | |
| AR088382A1 (es) | Formulaciones de etanercept estabilizadas con xilitol | |
| BR112015022861A2 (pt) | inibidores de bromodomínio | |
| EA201591003A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| CR10975A (es) | Formulaciones para el tratamiento del cancer | |
| CY1122313T1 (el) | Ορβεπιταντη για την αγωγη του χρονιου κνησμου | |
| PH12016500720A1 (en) | Stable formulation of insulin glulisine | |
| EA201591712A1 (ru) | Антибиотические композиции на основе цефтолозана | |
| EA201590617A1 (ru) | Композиции алкилированного циклодекстрина и способы их получения и применения | |
| MX2019004845A (es) | Procedimientos para la formacion de complejos de ciclodextrina para formular inhibidores del proteasoma peptidico. | |
| TR201910866T4 (tr) | Kanser tedavisi için birleşik preparasyonlar. | |
| AR125339A2 (es) | Compuesto inhibidor de la señalización de la trayectoria notch | |
| UY34895A (es) | Formulaciones estabilizadas de etanercept |